Press Releases

- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a

– Age-range for all EPIDIOLEX indications expanded to include patients  one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine –                      CARLSBAD, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:

LONDON and CARLSBAD, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on

 - Potential accelerated pathway to NDA submission -  - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest speakers to be held today from 10:00am-12:00pm EDT - CARLSBAD, Calif., June 30, 2020 (GLOBE NEWSWIRE)

GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD) Burden on patients, their families and healthcare professionals eased due to the reduction in controlled drug

LONDON and CARLSBAD, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors

LONDON and CARLSBAD, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive

- Total revenue of $120.6 million -  - Total Epidiolex® net product sales of $116.1 million -  - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and

LONDON and CARLSBAD, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive

CARLSBAD, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020